Literature DB >> 11878896

Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells.

Z Y Fang1, K Limbach, J Tartaglia, J Hammonds, X Chen, P Spearman.   

Abstract

Poxviruses that are attenuated for growth in human cells provide a safe means of HIV antigen expression and are capable of eliciting HIV-specific immune responses, including CD8+ cytotoxic T-lymphocyte (CTL) responses. HIV-1 antigen expression in human cells by attenuated poxvirus vectors may be limited by interferon-mediated host defense mechanisms. To enhance HIV antigen expression in human cells, the vaccinia virus E3L and K3L genes were inserted into a canarypox vector that expresses HIV-1 Gag, Env, and a Nef/Pol polyepitope string. E3L and K3L markedly reduced the activation of the double-stranded RNA-dependent protein kinase, PKR, and led to a significant reduction in apoptosis in HeLa cells. Production and release of HIV-1 antigen in the form of pseudovirions was enhanced in both duration and magnitude by this vector modification. The addition of immunomodulatory genes to attenuated poxviruses represents a novel strategy for enhancing antigen production by live vector HIV vaccine candidates. (C)2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11878896     DOI: 10.1006/viro.2001.1209

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Authors:  Nina D Russell; Barney S Graham; Michael C Keefer; M Juliana McElrath; Steve G Self; Kent J Weinhold; David C Montefiori; Guido Ferrari; Helen Horton; Georgia D Tomaras; Sanjay Gurunathan; Lynn Baglyos; Sharon E Frey; Mark J Mulligan; Clayton D Harro; Susan P Buchbinder; Lindsey R Baden; William A Blattner; Beryl A Koblin; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2007-02-01       Impact factor: 3.731

2.  Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.

Authors:  Xiugen Zhang; Farah Cassis-Ghavami; Mike Eller; Jeff Currier; Bonnie M Slike; Xuemin Chen; James Tartaglia; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

3.  Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.

Authors:  Xuemin Chen; Michael T Rock; Jason Hammonds; James Tartaglia; Ayumi Shintani; Jeff Currier; Bonnie Slike; James E Crowe; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses.

Authors:  Lynette S Chea; Linda S Wyatt; Sailaja Gangadhara; Bernard Moss; Rama R Amara
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

5.  Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Authors:  Simone Hornemann; Olof Harlin; Caroline Staib; Sigrid Kisling; Volker Erfle; Bernd Kaspers; Georg Häcker; Gerd Sutter
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  The genome of canarypox virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; G F Kutish; D L Rock
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

7.  A survey of host range genes in poxvirus genomes.

Authors:  Kirsten A Bratke; Aoife McLysaght; Stefan Rothenburg
Journal:  Infect Genet Evol       Date:  2012-12-23       Impact factor: 3.342

Review 8.  Poxviruses and the evolution of host range and virulence.

Authors:  Sherry L Haller; Chen Peng; Grant McFadden; Stefan Rothenburg
Journal:  Infect Genet Evol       Date:  2013-10-24       Impact factor: 3.342

9.  Co-expression of miRNA targeting the expression of PERK, but not PKR, enhances cellular immunity from an HIV-1 Env DNA vaccine.

Authors:  Adam K Wheatley; Marit Kramski; Marina R Alexander; Jesse G Toe; Rob J Center; Damian F J Purcell
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

Review 10.  Poxvirus tropism.

Authors:  Grant McFadden
Journal:  Nat Rev Microbiol       Date:  2005-03       Impact factor: 60.633

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.